What this means
This is a plan to test whether a supplement called MitoQ helps blood vessels, movement, and thinking in older adults. No results have been posted yet, so we do not know if it works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 65–80
- Where
- 1 site, including Connecticut
The science
- Registered title
- The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
- Trial ID
- NCT06027554 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Frailty, Mild Cognitive Impairment, Aging
- What is tested
- Mitoquinone Mesylate, Placebo capsule
- Sponsor
- UConn Health
- Ages
- 65 Years to 80 Years
- Dates
- First posted Sep 7, 2023 · updated Aug 12, 2026
Registry summary
The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question[s] it aims to answer are:
- To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction
- To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels
- To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.
Sites (1)
- UConn Health, Farmington, Connecticut, United States